Weill Cornell Medical College is internationally recognized as a premier center for research and clinical care of patients with cancers of the blood (Lymphoma, Leukemia and Myeloma), and conducts more clinical research studies for these diseases than any of our regional peers
. We bring the most promising new drugs and treatment approaches to patients at our center, and our group is widely regarded as one of the leading lymphoma clinical and research programs in the world
. We have contributed to the development and FDA approval of nearly all of the recently available lymphoma therapeutics, provided new insights into the biology of lymphoma, brought "targeted" and "personalized" treatments forward, evaluated the use of new imaging modalities, and contributed to the understanding of the challenges facing lymphoma "survivors". Our lymphoma pathologists are leaders and teachers in the field, and our hematologist/oncologists and radiation oncologists provide state-of-the art clinical care in a highly personalized fashion.
We have currently undertaken several exciting new initiatives to improve the understanding of and treatment for lymphoma
. These efforts include: targeted antibody therapies for lymphoma; immune-based treatments, anti-angiogenic therapies that interfere with tumor blood vessel formation, novel oral agents which affect
"What excites me is to study lymphoma from both basic science and clinical perspectives. That is what motivates my research and clinical practice. To design a new therapeutic approach that is beneficial to patients is what matters at the end of the day."
– Jia Ruan, M.D., Ph.D.
Assistant Professor of Clinical Medicine
Weill Cornell Medical College
the "switches" that regulate tumor cell growth, new drug development across the spectrum of lymphoma, epigenetic (gene regulation) based treatments; and novel strategies to predict patient outcomes and assess response to therapy. Several of the agents and treatment strategies that we conceived or helped to develop are currently being evaluated in large international trials and may ultimately become standard of care. At Weill Cornell, nearly 875 new patients with cancers of the blood are treated annually. Nearly one-third of our patients with leukemia, lymphoma, or myeloma are involved in clinical trials – a number which exceeds the participation rates at most other cancer centers. This is a reflection of our commitment to bringing better treatments to our patients
and of the exciting opportunities that our research programs provide to those with lymphoma.
World-class researchers at Weill Cornell are collaborating to find ways to stop cancer before it ever has the chance to gain a foothold, and to have better ways to treat it when it occurs
. Despite significant progress made to date, cancer remains the second leading cause of death in the United States. In 2009, there were nearly 13 million new cases of cancer diagnosed worldwide. Our research programs are based on remarkable collaborations between laboratory and clinical scientists – working together to take information from patients to our labs – and then bringing these laboratory findings back to the clinic to help our patients. We emphasize multidisciplinary collaborations – bringing together the best minds working on metastasis, obesity and cancer, tumor metabolism and stem cell research, among others.
The Lymphoma Program at NewYork-Presbyterian Hospital/Weill Cornell Medical Center is a clinical and research "Center of Excellence" dedicated to providing individualized, state-of-the-art comprehensive diagnostic and therapeutic approaches to all patients with non-Hodgkins lymphoma, Hodgkins Disease, multiple myeloma, Waldenstrom’s macroglobulinemia, chronic lymphocytic leukemia, monoclonal gammopathy and related disorders.
Harnessing the Power of Philanthropy
Bench-to-Bedside approaches promise to make a difference for patients – our ultimate goal at Weill Cornell Medical College. However – the ability to take specimens and other information from the patient to the laboratory, link experimental findings to treatment outcomes, development of new drugs, detailed tracking of outcomes, and assessing the ultimate impact of these advances on the lives of our patients – what we have now come to call "personalized medicine" is highly complex. This approach requires a well coordinated, multidisciplinary team, innovative scientists, advanced technology, sophisticated bioinformatics, and compassionate, capable caregivers to deliver these advances to our patients.
Support of our donors is essential in achieving the maximal impact of our novel approaches for our patients, and bringing new therapies to the clinic as quickly as possible. Your support will play a vital role, affecting the lives of cancer patients and their families for generations to come